Every 10-Q that Bioxytran Inc (BIXT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BIXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIXT filings page.
Bioxytran, Inc. is a clinical-stage, pre‑revenue pharmaceutical company focused on galectin inhibitors for COVID‑19 and other indications. For the six months ended June 30, 2026, it reported a net loss of $2,688,918 versus $1,318,196 a year earlier, driven by research and development of $480,958 and sharply higher general and administrative expenses of $2,106,695, including a $1,278,600 stock‑based performance grant to the CEO.
Cash declined to $177,384 from $509,914, with net cash used in operations of $588,383. Current liabilities were $5,274,697, producing a working capital deficit of $5,097,313 and an accumulated deficit of $23,733,164. The company discloses that these conditions raise substantial doubt about its ability to continue as a going concern and states that existing cash will not fund operations beyond approximately September 2026.
Bioxytran has one 2021 convertible note in default with $1,154,811 of principal and interest outstanding, a related derivative liability of $369,730, and significant potential dilution from approximately 68.4 million shares issuable on conversion, 32.6 million shares due for issuance, and 22.4 million warrants outstanding. During the first half of 2026 it raised about $314,533 net through unit private placements and continues to seek an additional $2–3 million of financing while advancing clinical programs in India and the U.S.
Bioxytran, Inc. reported a net loss of $2,068,989 for the three months ended March 31, 2026, or $0.02 per share, unchanged from the prior year’s loss per share. The company generated no revenue and remains a clinical-stage pharmaceutical developer.
Cash totaled $463,047 against current liabilities of $5,010,121, creating a negative working capital position of $4,547,075 and an accumulated deficit of $23,113,235, which raises substantial doubt about its ability to continue as a going concern. Bioxytran relies on equity and warrant financings and carries a defaulted $805,000 convertible note with an associated derivative liability of $476,489, pointing to significant potential dilution.
During the quarter, operating expenses rose sharply to $1,933,053, driven largely by $1,290,015 of stock-based compensation, including a substantial performance grant to the CEO. The company highlights statistically significant Phase 1b/2a data for its COVID-19 candidate ProLectin-M and plans Phase 3 and FDA trials, but indicates that advancing these programs depends on raising additional capital.
Bioxytran, Inc. filed its Q3 2025 report, highlighting continued losses and tight liquidity. The company posted a Q3 net loss of $282,726 and a nine‑month net loss of $1,600,922. Cash was $14,499 at September 30, 2025, with a negative working capital of $3,046,438, and management disclosed “substantial doubt” about the ability to continue as a going concern.
Total assets were $156,294, including intangibles of $141,795. Current liabilities were $3,060,937, driven by accounts payable, an embedded‑feature derivative liability of $419,206, and convertible notes payable and accrued interest totaling $1,046,433. The convertible note is convertible at the lesser of fixed thresholds with a price‑adjustment feature, implying potential issuance of approximately 15.1 million shares based on the stated conversion terms.
Common shares outstanding were 88,992,243 and preferred shares outstanding were 43,429,639 as of September 30, 2025. Warrants outstanding totaled 1,292,030. The filing also notes increased R&D spending of $452,000 for the nine months, reflecting ongoing development efforts.